scholarly journals Alzheimer-Plus

2003 ◽  
Vol 15 (1) ◽  
pp. 7-8 ◽  
Author(s):  
Hans Förstl

There is always hope—even now that immunization with beta-amyloid has not busted international psychogeriatrics; now that a term once so popular in European neuropsychiatry—“Parkinson plus”—has been de-constructed with the tools of a smart modern neurology (and that dementia with Lewy bodies has been reinvented); now that molecular biology has left some temporary responsibility for clinicians dealing with demented patients themselves, would it not be thrilling to attempt a fundamental reconsideration of some basic concepts of great—albeit temporary—practical relevance?

2019 ◽  
Vol 73 ◽  
pp. 74-81 ◽  
Author(s):  
Elijah Mak ◽  
Paul C. Donaghy ◽  
Elizabeth McKiernan ◽  
Michael J. Firbank ◽  
Jim Lloyd ◽  
...  

2012 ◽  
Vol 8 (4S_Part_5) ◽  
pp. P170-P171
Author(s):  
Kejal Kantarci ◽  
David Jones ◽  
Bradley Boeve ◽  
Prashanthi Vemuri ◽  
Mary Machulda ◽  
...  

2005 ◽  
Vol 32 (S 4) ◽  
Author(s):  
P Häussermann ◽  
A.O Ceballos-Baumann ◽  
H Förstl ◽  
R Feurer ◽  
B Conrad ◽  
...  

Author(s):  
O. S. Levin ◽  
E. E. Vasenina ◽  
A. Sh. Chimagomedova ◽  
N. G. Dudchenko

Te lecture presents modern concept of the symptoms, diagnosis and treatment of dementia with Lewy bodies (DLB), which accounts for about 10% of cases of dementia. Te nosological status of DLB and the problem of ratio of DLB and Parkinson’s disease which, apparently, represent two phenotypic variants of one neurodegenerative process («diseases with Lewy bodies») are considered in historical aspect. Approaches to the diagnosis and coding of DLB in accordance with ICD-10 are proposed. Te role of cholinesterase inhibitors, antipsychotics, levodopa, rasagiline and other drugs in the treatment of patients with DLB is аnalyzed.


Sign in / Sign up

Export Citation Format

Share Document